During the study follow‐up period, 12,605 female patients with breast cancer had a new‐onset of IHD, including 63 (1.05%) patients receiving GnRH agonists and 12,542 (7.52%) patients not receiving GnRH agonists. The gene discussed is GNRH1; the disease is breast carcinoma.